145 results
8-K
EX-10.1
IMUX
Immunic Inc
12 Jun 20
Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
4:05pm
Prospectus Supplement or intends to commence a proceeding for any such purpose.
(b) Assurances. The Original Registration Statement, as amended … , of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending
8-K
EX-10.3
IMUX
Immunic Inc
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
that is established for this purpose and signed by both Parties.
Seller shall procure that within 6 months after the Purchaser has exercised its option … purpose of any of the Sold IP and for the non-infringement of any third party right by any of the Sold IP or its use.
To the knowledge of the Seller
S-8
IMUX
Immunic Inc
25 May 18
Registration of securities for employees
4:33pm
as the Registrant’s board of directors may determine.
Estimated in accordance with paragraphs (c) and (h) of Rule 457 solely for the purpose … , 333-211359 and 333-218298
This Registration Statement is being filed for the purpose of increasing the number of securities of the same class
8-K
EX-10.2
IMUX
Immunic Inc
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
" has the meaning ascribed to such term in Article 3.02 (Demands and payments).
"Security" means any mortgage, land charge (including security purpose … )
those benefits will constitute reasonably equivalent value and fair consideration for the purpose of any Fraudulent Transfer Law.
United States
8-K
EX-10.1
IMUX
Immunic Inc
27 Apr 20
Immunic, Inc. Announces Pricing of $15 Million Financing
5:00pm
Prospectus Supplement or intends to commence a proceeding for any such purpose.
(b) Assurances. The Original Registration Statement, as amended … , of the institution or threatened institution of any proceeding for any such purpose, or of any request by the Commission for the amending
8-K
EX-10.6
m7vuj
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
S-8
EX-4.3
sk1cpjayru uv2ju03be
28 Jul 21
Registration of securities for employees
5:09pm
8-K
EX-3.2
0byfhlvx3voy7jqsl1x
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
8-K
EX-10.5
qefhqj
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
S-4/A
EX-8.2
vhbek2zyzh3s g0l9im
14 Feb 19
Registration of securities issued in business combination transactions (amended)
9:02am
425
EX-10.1
gia3i3u ap
7 Jan 19
Business combination disclosure
6:05am
8-K
EX-10.1
d0piukig 15k5rs
7 Jan 19
Vital Therapies and Immunic Therapeutics Announce Transaction to Create Leading Inflammatory and Autoimmune Disease Company
6:07am
8-K
EX-10.1
lsvrjf3peuzegfz
20 Oct 20
EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy
7:19am
8-K
EX-10.1
6ha6onrtlaz2mzc31a
14 Jan 19
Departure of Directors or Certain Officers
4:51pm
8-K
EX-10.1
lskb bxaq
12 Oct 18
Vital Therapies Provides Strategic Update
12:00am
8-K
EX-3.1
n747dqt2bra
17 Jul 19
Updated Unaudited Pro Forma Condensed Combined Financial Information
5:15pm
PRE 14A
ayhsua0ddmcf1mqwx6l
24 Jan 24
Preliminary proxy
5:05pm
8-K
EX-10.1
5z4a5b dnecf4hq5o5v
11 Oct 22
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
8:30am